PD-1 Inhibition in metastatic high tumour mutational burden (TMB) leiomyosarcoma with clinicopathological correlates.

Abstract

Leiomyosarcoma (LMS) is a subtype of sarcoma derived from smooth muscle cells. Unfortunately, this malignancy has a high rate of metastatic disease. Palliative systemic therapy has historically relied on cytotoxic agents such as doxorubicin, which have low rates of response. Immunotherapy has not been shown to be effective for most patients with sarcoma, including those with LMS. However, this has not been well described for patients with LMS and high tumour mutational burden (TMB). Herein, we report the case of a woman in her late 50s with metastatic high TMB (>10) leiomyosarcoma treated with pembrolizumab.

• Authors: Divita Pandita, Mrugakshi Dave, Brian Schulte
• Journal: BMJ case reports (BMJ Case Rep) Vol. 16 Issue 11 (Nov 17 2023) ISSN: 1757-790X [Electronic] England
• PMID: 37977843 (Publication Type: Case Reports, Journal Article)
• Copyright: © BMJ Publishing Group Limited 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Chemical References

• Programmed Cell Death 1 Receptor
• Biomarkers, Tumor

Topics

• Female
• Humans
• Programmed Cell Death 1 Receptor
• Leiomyosarcoma (drug therapy, genetics)
• Mutation
• Soft Tissue Neoplasms
• Neoplasms, Second Primary
• Biomarkers, Tumor